Full-Time
ML-driven software for small molecule ADMET
$210k - $250k/yr
Boston, MA, USA + 2 more
More locations: San Francisco, CA, USA | New York, NY, USA
In Person
| , |
Inductive Bio uses machine learning on a proprietary, curated dataset to help pharmaceutical, biotech, and research teams design small molecule drugs. Its platform provides real-time ADMET predictions and data-driven insights to guide drug design throughout development. The system stands out by pairing a thoroughly curated ADMET dataset with ML models in a user-friendly platform that supports entire teams, not just data scientists. The goal is to accelerate the discovery and optimization of safe, effective small molecule drugs by delivering practical, data-driven guidance during development.
Company Size
11-50
Company Stage
Series A
Total Funding
$29.3M
Headquarters
San Francisco, California
Founded
2021
Help us improve and share your feedback! Did you find this helpful?
People at Inductive Bio who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
Commuter Benefits
Phone/Internet Stipend
Home Office Stipend
Flexible Work Hours
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Unlimited Paid Time Off
401(k) Retirement Plan
401(k) Company Match
Company Equity
Stock Options
Wellness Program
Mental Health Support
Professional Development Budget
Conference Attendance Budget
Tuition Reimbursement
Professional Certification Support
Training Programs
Pet Insurance
Adoption Assistance
Family Planning Benefits
Fertility Treatment Support
Parental Leave
Relocation Assistance
Employee Discounts
Meal Benefits
Gym Membership
Team to develop and validate computational models trained on data from organoids and advanced human model systems that will improve drug safety and reduce reliance on animal testing
Inductive Bio has secured up to $21 million in funding to develop AI-driven drug toxicity models that could transform safety assessments in drug discovery. The initiative, called DATAMAP, involves collaboration with Amgen, Cincinnati Children's Hospital Medical Center, Baylor College of Medicine and Torch Bio. The project aims to reduce reliance on animal testing by using human-derived data from organoid systems to predict drug safety more accurately. Currently, nearly 90% of clinical-stage drug candidates fail to reach market, with 25% failing due to unforeseen safety issues. The initial phase will focus on drug-induced liver injury and cardiotoxicity, which account for over 40% of drug withdrawals. Inductive Bio will work with the FDA to validate these AI models for regulatory approval, aligning with the agency's push to modernise drug development methodologies.
Inductive Bio has secured $25M in Series A funding led by Obvious Ventures, with participation from a16z Bio + Health, Lux Capital, and others. The company aims to transform drug discovery with its collaborative AI platform, which accelerates compound optimization by predicting molecular behavior before lab synthesis. This approach reduces costs and speeds up drug development. Inductive Bio's platform has shown success in the Polaris ADMET competition and plans to expand its team and platform reach.
Inductive Bio raises $25M in Series A funding.
Inductive Bio has secured $25 million in Series A financing to expand its machine learning platform for small molecule drug discovery.